| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/10/2004 | CA2506984A1 Polyphosphazene immunocstimulants |
| 06/10/2004 | CA2506978A1 Method for counteracting a pathologic change in the b-adrenergic pathway |
| 06/10/2004 | CA2506949A1 Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
| 06/10/2004 | CA2506948A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 06/10/2004 | CA2506895A1 Cannabinoid receptor ligands |
| 06/10/2004 | CA2506888A1 Selective cyclooxygenase-2 inhibitor patch |
| 06/10/2004 | CA2506749A1 Method of drug loading in liposomes by gradient |
| 06/10/2004 | CA2506746A1 Method of drug loading in liposomes by gradient |
| 06/10/2004 | CA2506707A1 Mapks as modifiers of the rac, axin, and beta-catenin pathways and methods of use |
| 06/10/2004 | CA2506651A1 Efficient method for producing compositions enriched in total phenols |
| 06/10/2004 | CA2506628A1 Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor, e.g. parecoxib, valdecoxib and benzopyran derivatives |
| 06/10/2004 | CA2506611A1 External composition containing polyunsaturated fatty acid or its salt or ester |
| 06/10/2004 | CA2506607A1 Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| 06/10/2004 | CA2506524A1 Pyrazoloquinolines with immunomodulating activity |
| 06/10/2004 | CA2506194A1 Target for therapy of cognitive impairment |
| 06/10/2004 | CA2505542A1 Mandelic acid derivatives |
| 06/10/2004 | CA2503246A1 Compositions and methods for diagnosing and treating mood disorders |
| 06/10/2004 | CA2502970A1 Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| 06/10/2004 | CA2501493A1 Control of cancer with annonaceous extracts |
| 06/10/2004 | CA2501287A1 Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor, e.g. parecoxib and valdecoxib |
| 06/10/2004 | CA2500940A1 Use of iminosugar derivatives to inhibit ion channel activity |
| 06/10/2004 | CA2498566A1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/10/2004 | CA2485950A1 Methods for cohort selection and longevity studies |
| 06/09/2004 | EP1426762A1 Remedies for heart diseases |
| 06/09/2004 | EP1426380A1 Association compound of trehalose or maltitol with metal ion compound |
| 06/09/2004 | EP1426375A2 Analgesic spiroindole derivatives |
| 06/09/2004 | EP1426374A1 Naphthyridine derivative |
| 06/09/2004 | EP1426373A1 Method for producing the anticholinergic agent tiotropium bromide |
| 06/09/2004 | EP1426370A1 Propanolamine derivative having 1,4 benzodioxane ring |
| 06/09/2004 | EP1426361A1 Novel composition containing a bi-cyclic compound and a glyceride |
| 06/09/2004 | EP1426360A1 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same |
| 06/09/2004 | EP1426355A1 Crystals of hydroxynorephedrine derivative |
| 06/09/2004 | EP1426060A1 Remedies for allergic diseases |
| 06/09/2004 | EP1426059A1 Remedies for pruritus |
| 06/09/2004 | EP1426053A1 Use of amphiphilic lipids for reducing tumor metastasis |
| 06/09/2004 | EP1426052A1 Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| 06/09/2004 | EP1426051A1 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy |
| 06/09/2004 | EP1426050A1 Jnk inhibitors |
| 06/09/2004 | EP1426049A1 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| 06/09/2004 | EP1426048A2 Treating hypertriglyceridemia with RXR agonists in combination with a PPARgamma agonist |
| 06/09/2004 | EP1426047A1 Anti-tumour pharmaceutical composition comprising N-vanillyl fatty acid amide |
| 06/09/2004 | EP1426046A1 Novel use of tricyclic compound |
| 06/09/2004 | EP1426044A1 Use of esters of L-carnitine or alkanoyl L-carnitines as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 06/09/2004 | EP1426034A1 Hair growth tonic |
| 06/09/2004 | EP1425582A1 Diagnostic markers for ischemia |
| 06/09/2004 | EP1425408A2 Chemo-enzymatic synthesis of sialylated oligosaccharides |
| 06/09/2004 | EP1425399A2 Combinatorial methods for inducing cancer cell death |
| 06/09/2004 | EP1425381A2 Emu-based formulations for wound treatment related application information |
| 06/09/2004 | EP1425308A2 Polysaccharidic esters of retinoic acid |
| 06/09/2004 | EP1425287A1 Processes for preparing calcium salt forms of statins |
| 06/09/2004 | EP1425286A1 Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of diseases |
| 06/09/2004 | EP1425284A2 Furo- and thienopyrimidine derivatives as angiogenesis inhibitors |
| 06/09/2004 | EP1425283A1 Novel 4-aminofuropyrimidines and the use thereof |
| 06/09/2004 | EP1425281A1 Chemical compounds |
| 06/09/2004 | EP1425280A2 Hetero-bicyclic crf antagonists |
| 06/09/2004 | EP1425279A2 Method for the preparation of crystalline tetrahydrobenzothiepines |
| 06/09/2004 | EP1425277A2 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain |
| 06/09/2004 | EP1425272A1 Optical isomers of an iloperidone metabolite |
| 06/09/2004 | EP1425270A2 Methods and intermediates for preparing 4-aminoquinoline cetp inhibitors |
| 06/09/2004 | EP1425267A2 C2-substituted indane-1-ones and their derivatives, method for their production and their use as medicaments |
| 06/09/2004 | EP1425266A1 C2-substituted indane-1-ols and their derivatives, method for their production and their use as medicaments |
| 06/09/2004 | EP1425265A1 Derivatives of c2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments |
| 06/09/2004 | EP1425264A1 C2-disubstituted indane-1-ol systems, method for their production and their use as medicaments |
| 06/09/2004 | EP1425258A2 Hydroxyeicosenoic acid analogs |
| 06/09/2004 | EP1425256A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions |
| 06/09/2004 | EP1425068A1 Systemical administration of some oxazolidinones, e.g. linezolid, for the treatment of ocular infections |
| 06/09/2004 | EP1425046A2 Wild-type ras as a cancer therapeutic agent |
| 06/09/2004 | EP1425043A1 Method of increasing the presence of glutathione in cells |
| 06/09/2004 | EP1425036A2 Virus coat protein/receptor chimeras and methods of use |
| 06/09/2004 | EP1425035A1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 06/09/2004 | EP1425034A1 Method for treating coumarin-induced hemorrhage |
| 06/09/2004 | EP1425030A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof |
| 06/09/2004 | EP1425029A1 Peptidomimetics of biologically active metallopeptides |
| 06/09/2004 | EP1425028A2 Use of il-18 inhibitors for the treatement or prevention of sepsis |
| 06/09/2004 | EP1425023A1 G protein-coupled receptor assay |
| 06/09/2004 | EP1425022A1 Mutagenic nucleoside analogs for the treatment of viral disease |
| 06/09/2004 | EP1425021A1 Physiological method of improving vision |
| 06/09/2004 | EP1425020A1 Methods and compositions for treating apoptosis associated disorders |
| 06/09/2004 | EP1425019A1 Pharmaceutical composition |
| 06/09/2004 | EP1425018A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof |
| 06/09/2004 | EP1425017A1 Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| 06/09/2004 | EP1425016A2 Compositions and methods of treatment of cancer |
| 06/09/2004 | EP1425014A1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators |
| 06/09/2004 | EP1425012A1 Antihelminthic drugs as a treatment for hyperproliferative diseases |
| 06/09/2004 | EP1425011A2 Enhancement of learning and memory and treatment of amnesia |
| 06/09/2004 | EP1425010A1 Substituted indoles and their use as integrin antagonists |
| 06/09/2004 | EP1425009A2 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 06/09/2004 | EP1425008A1 Use of substituted aminomethyl chromans in the treatment of movement disorders |
| 06/09/2004 | EP1425007A1 Use of c2-substituted indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity |
| 06/09/2004 | EP1425005A1 Pharmaceutical compostion comprising lumiracoxib |
| 06/09/2004 | EP1425004A1 Use of compounds as functional antagonists to the central cannabinoid receptors |
| 06/09/2004 | EP1425003A1 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| 06/09/2004 | EP1425002A1 Aryloxypropylamines as chemosensitizing agents in the treatment of cancer |
| 06/09/2004 | EP1425001A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 06/09/2004 | EP1425000A1 Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity |
| 06/09/2004 | EP1424999A1 Use of c2-substituted indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity |
| 06/09/2004 | EP1424998A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 06/09/2004 | EP1424996A1 Method for the production of inhalation powders |
| 06/09/2004 | EP1424994A1 Preparation of sustained release pharmaceutical composition |
| 06/09/2004 | EP1424985A1 Use of derivatives of c2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity |